ACAD vs INCY
ACADIA Pharmaceuticals Inc. vs Incyte — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
| Metric | ACAD | INCY |
|---|
| AI Score |
69
|
72
|
| Price |
$29.41
|
$121.08
|
| P/E Ratio |
13.07×
|
14.89×
|
| ROE |
31.9%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
92.6%
|
| Debt / Equity |
0.06×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
56.2
|
| Beta |
0.845
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus INCY.
INCY leads by 3 points.
INCY scores 72/100 (Buy) versus ACAD at 69/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical